Skip to main content
Miracle Leaf

Miracle Leaf® qualifying-conditions guide

Medical Marijuana for Alzheimer's Disease

Progressive neurodegenerative disease and the most common cause of dementia. Cannabis has limited evidence for managing behavioral and psychological symptoms of dementia (agitation, sleep disturbance, appetite loss); no evidence demonstrates disease-modifying effects.

Reviewed by Miracle Leaf® Editorial Team

Last reviewed 2026-05-15

NASEM evidence levelLimitedICD-10: G30

What is Alzheimer's Disease?

Alzheimer's disease is a progressive neurodegenerative disorder and the most common cause of dementia, affecting an estimated 6.7 million Americans over age 65. Pathologically, the disease is characterized by amyloid plaques and tau-protein neurofibrillary tangles in the brain. Symptoms include memory loss, language difficulty, executive dysfunction, and (in later stages) behavioral and psychological symptoms of dementia (BPSD) such as agitation, aggression, sleep disturbance, and appetite loss.

Disease-modifying therapies (anti-amyloid antibodies) provide modest benefit at early stages. Most clinical care remains symptomatic.

Does cannabis help Alzheimer's Disease?

Evidence for cannabis or cannabinoids in Alzheimer's disease is limited and focused on symptomatic management of BPSD rather than disease modification. Small open-label studies have reported improvements in agitation, sleep, and appetite with oral cannabinoids (dronabinol, nabilone). No large randomized controlled trials have demonstrated cognitive benefit, disease-progression delay, or neuroprotective effects.

Alzheimer's disease, dementia, or "agitation of Alzheimer's" is a qualifying condition under several state medical cannabis programs. Caregivers should coordinate use with the patient's geriatric care team given the elevated risk of cognitive side effects and falls in this population.

Eligibility

State eligibility for Alzheimer's Disease

Whether this condition is listed varies by state program. A Miracle Leaf® physician determines eligibility during your evaluation.

State-by-state eligibility for Alzheimer's Disease: whether the condition qualifies under Florida, Georgia, and Texas medical cannabis programs.
StateQualifies?Program
FloridaNot listedFlorida OMMU
GeorgiaYesGeorgia DPH Low-THC Registry
TexasYesTexas Compassionate Use Program
Outside Florida, Georgia, or Texas?

Telehealth visits are available in 22 states. See telehealth states

Common questions

Frequently asked questions

What does the evidence base say about cannabis for Alzheimer's disease?
Cannabis evidence in Alzheimer's is limited. The 2017 NASEM report did not identify high-tier evidence for cannabis as treatment of Alzheimer's disease. Available studies suggest possible benefit for behavioral and psychological symptoms of dementia (BPSD) (agitation, sleep disturbance, appetite loss) but trials are small and outcomes inconsistent.
Is any cannabis-derived product FDA-approved for Alzheimer's?
No. No cannabis or cannabinoid product is FDA-approved for any indication in Alzheimer's disease. Disease-modifying therapies for early Alzheimer's (anti-amyloid antibodies such as lecanemab and donanemab) are unrelated to cannabis.
Are there practical concerns when older adults with dementia use cannabis?
Yes. Older adults are more susceptible to sedation, orthostatic hypotension, falls, confusion, and drug interactions. Cannabis can interact with anticholinergics, sedatives, and antipsychotics commonly prescribed in dementia care. THC-dominant products can worsen cognition and disorientation. Caregivers and clinicians should weigh symptom-management benefit against fall and cognitive risk.
Does cannabis slow or prevent Alzheimer's progression?
No. There is no clinical evidence that cannabis or cannabinoids slow, prevent, or reverse Alzheimer's disease progression. Any role for cannabis in Alzheimer's care is symptomatic (addressing agitation, sleep, or appetite) not disease-modifying.

Ready to talk with a Miracle Leaf® physician?

Reviewed by Miracle Leaf® Editorial Team. This page summarizes current peer-reviewed evidence and federal guidance and is updated when the source documents materially change.